SG11201803934YA - Compositions and methods for expression of multiple biologically active polypeptides from a single vector for treatment of cardiac conditions and other pathologies - Google Patents
Compositions and methods for expression of multiple biologically active polypeptides from a single vector for treatment of cardiac conditions and other pathologiesInfo
- Publication number
- SG11201803934YA SG11201803934YA SG11201803934YA SG11201803934YA SG11201803934YA SG 11201803934Y A SG11201803934Y A SG 11201803934YA SG 11201803934Y A SG11201803934Y A SG 11201803934YA SG 11201803934Y A SG11201803934Y A SG 11201803934YA SG 11201803934Y A SG11201803934Y A SG 11201803934YA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- rule
- compositions
- expression
- biologically active
- Prior art date
Links
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 6
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 6
- 239000000203 mixture Substances 0.000 title abstract 4
- 229920001184 polypeptide Polymers 0.000 title abstract 4
- 238000000034 method Methods 0.000 title abstract 3
- 239000013598 vector Substances 0.000 title abstract 3
- 230000000747 cardiac effect Effects 0.000 title abstract 2
- 230000007170 pathology Effects 0.000 title 1
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 208000020446 Cardiac disease Diseases 0.000 abstract 1
- 102000019034 Chemokines Human genes 0.000 abstract 1
- 108010012236 Chemokines Proteins 0.000 abstract 1
- 102000004127 Cytokines Human genes 0.000 abstract 1
- 108090000695 Cytokines Proteins 0.000 abstract 1
- 230000002491 angiogenic effect Effects 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000013604 expression vector Substances 0.000 abstract 1
- 208000019622 heart disease Diseases 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 102000040430 polynucleotide Human genes 0.000 abstract 1
- 108091033319 polynucleotide Proteins 0.000 abstract 1
- 239000002157 polynucleotide Substances 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4728—Calcium binding proteins, e.g. calmodulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A61K38/1738—Calcium binding proteins, e.g. calmodulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1858—Platelet-derived growth factor [PDGF]
- A61K38/1866—Vascular endothelial growth factor [VEGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/195—Chemokines, e.g. RANTES
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0028—Disruption, e.g. by heat or ultrasounds, sonophysical or sonochemical activation, e.g. thermosensitive or heat-sensitive liposomes, disruption of calculi with a medicinal preparation and ultrasounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/521—Chemokines
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/50—Fusion polypeptide containing protease site
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/002—Vectors comprising a special translation-regulating system controllable or inducible
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/007—Vectors comprising a special translation-regulating system cell or tissue specific
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Toxicology (AREA)
- Immunology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Vascular Medicine (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Cardiology (AREA)
- Marine Sciences & Fisheries (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562254139P | 2015-11-11 | 2015-11-11 | |
| PCT/US2016/061668 WO2017083750A1 (en) | 2015-11-11 | 2016-11-11 | Compositions and methods for expression of multiple biologically active polypeptides from a single vector for treatment of cardiac conditions and other pathologies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201803934YA true SG11201803934YA (en) | 2018-06-28 |
Family
ID=57543150
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201803934YA SG11201803934YA (en) | 2015-11-11 | 2016-11-11 | Compositions and methods for expression of multiple biologically active polypeptides from a single vector for treatment of cardiac conditions and other pathologies |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US11154622B2 (https=) |
| EP (1) | EP3387010A1 (https=) |
| JP (1) | JP6976244B2 (https=) |
| KR (1) | KR20180069081A (https=) |
| CN (1) | CN108713025A (https=) |
| AU (1) | AU2016353342B2 (https=) |
| BR (1) | BR112018009645A2 (https=) |
| CA (1) | CA3004742A1 (https=) |
| HK (1) | HK1259137A1 (https=) |
| MA (1) | MA43404A (https=) |
| MX (1) | MX2018005886A (https=) |
| RU (1) | RU2758489C2 (https=) |
| SG (1) | SG11201803934YA (https=) |
| WO (1) | WO2017083750A1 (https=) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3021572A1 (en) | 2016-04-20 | 2017-10-26 | Centro De Investigaciones Energeticas, Medioambientales Y Tecnologicas | Compositions and methods for enhanced gene expression of pklr |
| KR20190102259A (ko) | 2017-01-10 | 2019-09-03 | 인트렉손 코포레이션 | 신규의 유전자 스위치 발현 시스템을 통한 폴리펩티드의 발현 조절 |
| KR102712841B1 (ko) * | 2017-09-29 | 2024-10-04 | (주)벳바젠 | 심부전의 예방 또는 치료용 약학적 조성물 |
| EP3697452A4 (en) | 2017-10-16 | 2021-11-24 | Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, O.A., M.P. | LENTIVIRAL VECTORS FOR ADMINISTRATION OF PKLR TO TREAT PYRUVATE KINASE DEFECTS |
| WO2019173465A1 (en) | 2018-03-06 | 2019-09-12 | Intrexon Corporation | Human papillomavirus vaccines and uses of the same |
| IL277128B2 (en) | 2018-03-06 | 2025-11-01 | Precigen Inc | Hepatitis b vaccines and uses of the same |
| BR112020020841A2 (pt) | 2018-04-11 | 2021-01-19 | Fundacion Para La Investigacion Biomedica Del Hospital Infantil Universitario Nino Jesus | Composições e métodos para transplante de célulastronco |
| CA3096293A1 (en) | 2018-04-27 | 2019-10-31 | Rocket Pharmaceuticals, Ltd. | Gene therapy for cns degeneration |
| US20210220463A1 (en) * | 2018-05-18 | 2021-07-22 | UNIVERSITé LAVAL | Vectors for dna vaccination |
| US12528848B2 (en) * | 2018-05-25 | 2026-01-20 | The Wistar Institute Of Anatomy And Biology | Tumor-specific neoantigens and methods of using the same |
| AU2019354391A1 (en) | 2018-10-01 | 2021-05-06 | Adicet Therapeutics, Inc. | Compositions and methods regarding engineered and non- engineered γδ-Τ cells for treatment of hematological tumors |
| CN113272016A (zh) | 2018-10-01 | 2021-08-17 | 阿迪塞特生物股份有限公司 | 关于治疗实体肿瘤的工程化和非工程化γδ-T细胞的组合物和方法 |
| IL286675B2 (en) * | 2019-03-29 | 2026-02-01 | Abiomed Inc | Systems and methods for left ventricular unloading in biological therapy or vector gene therapy |
| CN114450411A (zh) | 2019-04-01 | 2022-05-06 | 特纳亚治疗股份有限公司 | 具有工程化衣壳的腺相关病毒 |
| US20210290753A1 (en) * | 2019-05-21 | 2021-09-23 | UNIVERSITé LAVAL | Crimean-congo hemorrhagic fever virus immunogenic compositions |
| JP7717677B2 (ja) * | 2019-08-07 | 2025-08-04 | ノースウェスタン ユニバーシティ | 心臓内遺伝子送達のための材料及び方法 |
| KR20220066914A (ko) * | 2019-09-20 | 2022-05-24 | 유씨엘 비즈니스 리미티드 | 부정맥 유발성 우심실 심근병증의 유전자 요법 조성물 및 치료 |
| IL297391A (en) | 2020-04-20 | 2022-12-01 | Tenaya Therapeutics Inc | An adeno-associated virus with an engineered capsid |
| JP2023538519A (ja) | 2020-08-07 | 2023-09-08 | スペースクラフト セブン リミテッド ライアビリティ カンパニー | Ａａｖベクターを使用したプラコフィリン－２（ｐｋｐ２）遺伝子治療 |
| IL301675A (en) | 2020-10-09 | 2023-05-01 | Tenaya Therapeutics Inc | Methods and preparations for placophilin-2 gene therapy |
| US11781156B2 (en) * | 2020-10-09 | 2023-10-10 | Tenaya Therapeutics, Inc. | Plakophillin-2 gene therapy methods and compositions |
| AU2022325237A1 (en) * | 2021-08-12 | 2024-03-21 | Renovacor, Inc. | Retrograde coronary venous or sinus administration of therapeutics |
| WO2023232984A1 (en) * | 2022-06-02 | 2023-12-07 | Patrick Most | S100a1 protein for use in treating and preventing infarct extension |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4985461A (en) | 1985-10-21 | 1991-01-15 | Rohm And Haas Company | Insecticidal N'-substituted-N,N'-diacylhydrazines |
| US5117057A (en) | 1985-10-21 | 1992-05-26 | Rohm And Haas Company | Insecticidal N' substituted-N-N'-disubstituted-hydrazines |
| US5225443A (en) | 1986-05-01 | 1993-07-06 | Rohm And Haas Company | Insecticidal N'-substituted-N'-substituted N,N'-diacylhydrazines |
| US5542935A (en) * | 1989-12-22 | 1996-08-06 | Imarx Pharmaceutical Corp. | Therapeutic delivery systems related applications |
| IL100643A (en) | 1991-01-25 | 1996-10-31 | Nippon Kayaku Kk | History of hydrazine and pesticides containing these histories as an active ingredient |
| US5530028A (en) | 1992-11-23 | 1996-06-25 | Rohm And Haas Company | Insecticidal N'-substituted-N,N'-diacylhydrazines |
| US6013836A (en) | 1992-02-28 | 2000-01-11 | Rohm And Haas Company | Insecticidal N'-substituted-N,N'-disubstitutedhydrazines |
| JP5031967B2 (ja) | 2000-03-22 | 2012-09-26 | イントレキソン コーポレーション | 新規エクジソン受容体ベースの誘導性遺伝子発現系 |
| US20040033600A1 (en) | 2001-03-21 | 2004-02-19 | Palli Subba Reddy | Ecdysone receptor-based inducible gene expression system |
| US8105825B2 (en) | 2000-10-03 | 2012-01-31 | Intrexon Corporation | Multiple inducible gene regulation system |
| ES2424812T3 (es) | 2001-02-20 | 2013-10-08 | Intrexon Corporation | Receptores X retinoides quiméricos y su uso en un sistema inducible de expresión génica basado en receptores de ecdisona novedoso |
| CA2438133C (en) | 2001-02-20 | 2015-01-27 | Rheogene, Inc. | Novel substitution mutant receptors and their use in a nuclear receptor-based inducible gene expression system |
| EP1373470B1 (en) | 2001-02-20 | 2013-04-24 | Intrexon Corporation | Novel substitution mutant receptors and their use in a nuclear receptor-based inducible gene expression system |
| WO2002066613A2 (en) | 2001-02-20 | 2002-08-29 | Rheogene Holdings, Inc | Novel ecdysone receptor/invertebrate retinoid x receptor-based inducible gene expression system |
| US20030027751A1 (en) * | 2001-04-10 | 2003-02-06 | Genvec, Inc. | VEGF fusion proteins |
| WO2003027289A1 (en) | 2001-09-26 | 2003-04-03 | Rheo Gene Holdings, Inc. | Leafhopper ecdysone receptor nucleic acids, polypeptides, and uses thereof |
| CA2459807C (en) | 2001-09-26 | 2013-09-03 | Jianzhong Zhang | Whitefly ecdysone receptor nucleic acids, polypeptides, and uses thereof |
| US7375093B2 (en) | 2002-07-05 | 2008-05-20 | Intrexon Corporation | Ketone ligands for modulating the expression of exogenous genes via an ecdysone receptor complex |
| US7304161B2 (en) | 2003-02-10 | 2007-12-04 | Intrexon Corporation | Diaclhydrazine ligands for modulating the expression of exogenous genes in mammalian systems via an ecdysone receptor complex |
| US7304162B2 (en) | 2003-02-21 | 2007-12-04 | Intrexon Corporation | Oxadiazoline ligands for modulating the expression of exogenous genes via an ecdysone receptor complex |
| US7456315B2 (en) | 2003-02-28 | 2008-11-25 | Intrexon Corporation | Bioavailable diacylhydrazine ligands for modulating the expression of exogenous genes via an ecdysone receptor complex |
| US7935510B2 (en) | 2004-04-30 | 2011-05-03 | Intrexon Corporation | Mutant receptors and their use in a nuclear receptor-based inducible gene expression system |
| US9034650B2 (en) | 2005-02-02 | 2015-05-19 | Intrexon Corporation | Site-specific serine recombinases and methods of their use |
| PL2043662T3 (pl) | 2006-07-26 | 2016-03-31 | Intrexon Corp | Sposoby i kompozycje do leczenia choroby |
| US7719424B2 (en) | 2007-01-19 | 2010-05-18 | Igt | Table monitoring identification system, wager tagging and felt coordinate mapping |
| CN104761466A (zh) | 2007-05-29 | 2015-07-08 | 英特拉克森公司 | 通过蜕皮素受体复合物调节外源性基因表达的手性二酰基肼配体 |
| KR101666228B1 (ko) * | 2007-09-28 | 2016-10-13 | 인트렉손 코포레이션 | 생물치료학적 분자를 발현시키기 위한 치료학적 유전자-스위치 작제물 및 생물반응기, 및 이의 용도 |
| HUE035406T2 (en) | 2007-10-08 | 2018-05-02 | Intrexon Corp | Engineered dendritic cells and uses for the treatment of cancer |
| WO2009114702A2 (en) * | 2008-03-14 | 2009-09-17 | Humanzyme Limited | Recombinant production of authentic human proteins using human cell expression systems |
| CN102575227A (zh) | 2008-10-08 | 2012-07-11 | 英特瑞克斯顿股份有限公司 | 表达多种免疫调节剂的工程改造细胞及其应用 |
| CA2772610C (en) | 2009-08-28 | 2018-01-23 | The Cleveland Clinic Foundation | Sdf-1 delivery for treating ischemic tissue |
| CA2794196A1 (en) | 2010-03-23 | 2011-09-29 | Intrexon Corporation | Vectors conditionally expressing therapeutic proteins, host cells comprising the vectors, and uses thereof |
| SG10201600912SA (en) | 2011-03-04 | 2016-03-30 | Intrexon Corp | Vectors conditionally expressing protein |
| AU2012394394A1 (en) * | 2012-11-16 | 2015-06-04 | United Biomedical, Inc. | Synthetic peptide-based emergency vaccine against foot and mouth disease (FMD) |
| WO2014089121A2 (en) * | 2012-12-03 | 2014-06-12 | Thomas Ichim | Retrograde delivery of cells and nucleic acids for treatment of cardiovascular diseases |
| CN105377268A (zh) | 2013-03-15 | 2016-03-02 | 克利夫兰临床医学基金会 | 用于治疗心肌梗塞的sdf-1的逆行递送 |
| WO2016187585A1 (en) | 2015-05-20 | 2016-11-24 | Viventia Bio Inc. | Deimmunized linker and methods of use |
| CN105754990A (zh) * | 2016-01-29 | 2016-07-13 | 深圳精准医疗科技有限公司 | 一种pd-1/ctla-4双特异性抗体的制备方法及其应用 |
-
2016
- 2016-11-11 WO PCT/US2016/061668 patent/WO2017083750A1/en not_active Ceased
- 2016-11-11 AU AU2016353342A patent/AU2016353342B2/en not_active Ceased
- 2016-11-11 JP JP2018524443A patent/JP6976244B2/ja not_active Expired - Fee Related
- 2016-11-11 RU RU2018117674A patent/RU2758489C2/ru active
- 2016-11-11 HK HK19101096.0A patent/HK1259137A1/zh unknown
- 2016-11-11 MA MA043404A patent/MA43404A/fr unknown
- 2016-11-11 CA CA3004742A patent/CA3004742A1/en active Pending
- 2016-11-11 CN CN201680078586.0A patent/CN108713025A/zh active Pending
- 2016-11-11 EP EP16810130.1A patent/EP3387010A1/en not_active Withdrawn
- 2016-11-11 MX MX2018005886A patent/MX2018005886A/es unknown
- 2016-11-11 BR BR112018009645A patent/BR112018009645A2/pt not_active IP Right Cessation
- 2016-11-11 SG SG11201803934YA patent/SG11201803934YA/en unknown
- 2016-11-11 KR KR1020187016185A patent/KR20180069081A/ko not_active Withdrawn
-
2018
- 2018-05-11 US US15/978,036 patent/US11154622B2/en not_active Expired - Fee Related
-
2021
- 2021-09-22 US US17/481,938 patent/US20220072159A1/en not_active Abandoned
-
2023
- 2023-10-12 US US18/485,838 patent/US20240148908A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| KR20180069081A (ko) | 2018-06-22 |
| MX2018005886A (es) | 2018-08-15 |
| RU2758489C2 (ru) | 2021-10-28 |
| WO2017083750A1 (en) | 2017-05-18 |
| JP6976244B2 (ja) | 2021-12-08 |
| US11154622B2 (en) | 2021-10-26 |
| US20240148908A1 (en) | 2024-05-09 |
| JP2018536405A (ja) | 2018-12-13 |
| MA43404A (fr) | 2018-10-17 |
| US20220072159A1 (en) | 2022-03-10 |
| CN108713025A (zh) | 2018-10-26 |
| EP3387010A1 (en) | 2018-10-17 |
| RU2018117674A (ru) | 2019-12-13 |
| US20180360992A1 (en) | 2018-12-20 |
| AU2016353342A1 (en) | 2018-05-24 |
| RU2018117674A3 (https=) | 2020-04-20 |
| HK1259137A1 (zh) | 2019-11-29 |
| AU2016353342B2 (en) | 2021-04-01 |
| CA3004742A1 (en) | 2017-05-18 |
| BR112018009645A2 (pt) | 2018-11-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201803934YA (en) | Compositions and methods for expression of multiple biologically active polypeptides from a single vector for treatment of cardiac conditions and other pathologies | |
| SG11201901206SA (en) | Trimer stabilizing hiv envelope protein mutations | |
| SG11201803958WA (en) | Nucleic acids encoding repetitive amino acid sequences rich in proline and alanine residues that have low repetitive nucleotide sequences | |
| SG11201906297QA (en) | Nucleic acids encoding crispr-associated proteins and uses thereof | |
| SG11201908330PA (en) | Farnesoid x receptor agonists and uses thereof | |
| SG11201900349VA (en) | Somatostatin modulators and uses thereof | |
| SG11201804704PA (en) | Compositions and methods for decreasing tau expression | |
| SG11201811432WA (en) | Rna for cancer therapy | |
| SG11201811232XA (en) | Treatment of amd using aav2 variant with aflibercept | |
| SG11201908512YA (en) | Somatostatin modulators and uses thereof | |
| SG11201808622SA (en) | Chimeric receptors to flt3 and methods of use thereof | |
| SG11201809912UA (en) | Hybrid carriers for nucleic acid cargo | |
| SG11201804713VA (en) | TARGETING PEPTIDES FOR DIRECTING ADENO-ASSOCIATED VIRUSES (AAVs) | |
| SG11201809700YA (en) | Gdf15 fusion proteins and uses thereof | |
| SG11201805162VA (en) | Plasmid constructs for heterologous protein expression and methods of use | |
| SG11201903454VA (en) | Immunologically discernible cell surface variants for use in cell therapy | |
| SG11201811431VA (en) | Multispecific antibodies against cd40 and cd137 | |
| SG11201903882VA (en) | Il-2 variants for the treatment of autoimmune diseases | |
| SG11201805784PA (en) | Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases | |
| SG11201807489PA (en) | Cells expressing multiple chimeric antigen receptor (car) molecules and uses therefore | |
| SG11201803975SA (en) | Improved tnf binders | |
| SG11201805805VA (en) | Recombinogenic nucleic acid strands in situ | |
| SG11201811230RA (en) | Compositions and methods for reducing ocular neovascularization | |
| SG11201906271QA (en) | Potent and short promoter for expression of heterologous genes | |
| SG11201909856XA (en) | Mesenchymal lineage precursor or stem cells with enhanced immunosuppression |